Dual mechanism inhibitors for the treatment of disease
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
1. A compound of Formula (VI):
or a pharmaceutically acceptable salt thereof;
wherein
R 4 is methyl; and
n is 2.
2. The compound of claim 1 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
3. A composition comprising the compound of claim 1 .
4. The composition of claim 3 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethyl benzoate or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutically acceptable carrier is saline buffered to a pH of about 5.5 to about 6.5.
8. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (VI):
or a pharmaceutically acceptable salt thereof;
wherein
R 4 is methyl; and
n is 2.
9. The method of claim 8 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
10. The method of claim 8 , wherein the eye disease comprises glaucoma.
11. The method of claim 8 , wherein the eye disease comprises a neurodegenerative eye disease.
12. The method of claim 8 , wherein the eye disease comprises dry eye.
13. The method of claim 8 , wherein the eye disease comprises ocular hypertension.
14. The method of claim 8 , wherein the administration is topical administration to the eye.
15. A method of reducing intraocular pressure in an eye of a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (VI):
or a pharmaceutically acceptable salt thereof;
wherein
R 4 is methyl; and
n is 2.
16. The method of claim 15 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
17. The method of claim 15 , wherein the subject is suffering from glaucoma.
18. The method of claim 17 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
19. The method of claim 15 , wherein the subject is suffering from ocular hypertension.
20. The method of claim 19 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
21. The method of claim 15 , wherein the administration is topical administration to the eye.
22. A method of modulating kinase activity in a cell, comprising contacting the cell with an amount effective to modulate kinase activity of a compound of Formula (VI):
or a pharmaceutically acceptable salt thereof;
wherein
R 4 is methyl; and
n is 2.
23. The method of claim 22 , wherein the compound is 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.
24. The method of claim 22 , wherein the cell is in a subject.
25. The method of claim 24 , wherein the subject is a human.
26. The method of claim 22 , wherein the administration is topical administration.
27. The method of claim 22 , wherein the administration is systemic administration.
28. The method of claim 25 , wherein the human subject is suffering from glaucoma.
29. The method of claim 25 , wherein the human subject is suffering from a neurodegenerative eye disease.
30. The method of claim 25 , wherein the human subject is suffering from dry eye.
31. The method of claim 25 , wherein the human subject is suffering from ocular hypertension.